



Docket/Matter No. 56.US4.CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Applicant : DUMAS MILNE EDWARDS, et al.

Appl. No. : 09/978,360

Filed : October 15, 2001

Title : COMPLEMENTARY DNAs ENCODING PROTEINS
WITH SIGNAL PEPTIDES

Grp./A.U. : Unknown

Examiner : Unassigned

Honorable Commissioner of Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant submits the references listed on the attached forms PTO/SB/08A and 08B, copies of which are enclosed. This statement is being filed before the receipt of a first Office Action on the merits. The majority of the references were cited in International Search Reports (copies enclosed), and I, the undersigned, hereby certify that each of those items was cited in a communication from a foreign patent office in a counterpart foreign application.

The Commissioner is hereby authorized to charge any fees in connection with this document to our Deposit Account No.: 50-1181

Respectfully submitted,

GENSET CORPORATION

Date: 25 Jan, 2002

By: Carol Johns
Carol Johns, Ph.D.
Registration No. P-50,463

10665 Sorrento Valley Road
San Diego, CA 92121-1609

Telephone: (858) 597-2600

Facsimile: (858) 597-2601

e-mail: carol.johns@genxy.com

Certificate of Mailing under 37 CFR 1.10

Date of Deposit: Jan 25, 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, on the Date of Deposit shown above, postage prepaid and in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

C. M. McClure
Signature

C. M. McClure

Typed or Printed Name of Person Signing Certificate

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<div>Complete if Known</div> <table border="1"> <tr> <td>Application Number</td> <td>09/978,360</td> </tr> <tr> <td>Filing Date</td> <td>October 15, 2001</td> </tr> <tr> <td>First Named Inventor</td> <td>DUMAS MILNE EDWARDS, et al.</td> </tr> <tr> <td>Art Unit</td> <td>Unknown</td> </tr> <tr> <td>Examiner Name</td> <td>Unassigned</td> </tr> <tr> <td>Attorney Docket Number</td> <td>56.US4.CIP</td> </tr> </table>		Application Number	09/978,360	Filing Date	October 15, 2001	First Named Inventor	DUMAS MILNE EDWARDS, et al.	Art Unit	Unknown	Examiner Name	Unassigned	Attorney Docket Number	56.US4.CIP
Application Number	09/978,360																
Filing Date	October 15, 2001																
First Named Inventor	DUMAS MILNE EDWARDS, et al.																
Art Unit	Unknown																
Examiner Name	Unassigned																
Attorney Docket Number	56.US4.CIP																
<div>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div>(use as many sheets as necessary)</div>																	
Sheet	1	of	5														

[illegible]


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	76
		Country Code 3 - Number 4 - Kind Code 5 (if known)				
	C	EP 0 756 006 A2	01/29/1997	Inst.Genomic Rsrch.		
	D	WO 99/51727 A2	10/14/1977	Metagen Gesellschaft		
	E	WO 96/33276 A1	10/24/1996	Human Genome Sci.		
	F	WO 99/06550 A2	02/11/1999	Genset		
	G	WO 99/06548 A2	02/11/1999	Genset		
	H	WO 96/17925 A1	06/13/1996	Immunex Corp.		
	I	WO 90/14432 A1	11/29/1990	Genetics Institute		
	J	WO 96/41624 A1	12/27/1996	Immunex Corp.		
	K	WO 96/34981 A3	11/07/1996	Genset		
	L	WO 97/07198 A2	02/27/1997	Genetics Institute		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet <u>2</u> of <u>5</u>		Complete if Known	
		Application Number	09/978.360
		Filing Date	October 15, 2001
		First Named Inventor	DUMAS MILNE EDWARDS. et al.
		Group Art Unit	Unknown
		Examiner Name	Unassigned
		Attorney Docket Number	56.US4.CIP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	M	TASHIRO, et al.; "Signal Sequencing Trap: A Cloning Strategy for Secreted Proteins and Type I Membrane Proteins"; Science, Vol. 261, 30 July 1993; pgs. 600-603; XP000673204	
	N	YAN, et al.; "Membrane-anchored aspartyl protease with Alzheimer's disease B-secretase activity"; Nature, Vol. 402; 2 December 1999; pgs. 533-536	
	O	HUSSAIN, et al.; "Identification of a Novel Aspartic Protease (Asp2) as B-Secretase"; Molecular and Cellular Neuroscience 14, 419-427 (1999)	
	P	YOKOYAMA-KOBAYASHI et al.; "A signal sequence detection system using secreted protease activity as an indicator"; Gene, 163 (1995), 193-196; 1995 Elsevier Science B.V.; XP002053953	
	Q	LOCKHART, et al.; "Expression monitoring by hybridization to high-density oligonucleotide arrays"; Bio/Technology, Vol. 14; 14 December 1996; pgs. 1675-1680; XP002074420	
	R	VON HEIJNE, G.; "A new method for predicting signal sequence cleavage sites"; Nucleic Acids Research, Vol. 14, No. 11; 1986; pgs. 4683-4690; XP002053954	
	S	KATO, et al.; "Construction of a human full-length cDNA bank"; GENE; Vol. 150, 1994; pgs. 243-250; XP002081364	
	T	CARNINCI, et al.; "High-Efficiency Full-Length cDNA Cloning by Biotinylated CAP Trapper"; Genomics; Vol. 37, No. 3; 1 November 1996; pgs. 327-336; XP002081729	
	U	SINHA, et al.; "Purification and cloning of amyloid precursor protein B-secretase from human brain"; Nature, Vol. 402; 2 December 1999; pgs. 537-540	
	V	VASSAR, et al.; "B-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE"; Science, Vol. 286, 22 October 1999; pgs. 735-741	
	W	LIN, et al.; "Human aspartic protease memapsin 2 cleaves the B-Secretase site of B-Amyloid precursor protein"; PNAS Online, Vol. 97, Issue 4, pgs. 1456-1460; February 15, 2000	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/978.360
				Filing Date	October 15, 2001
				First Named Inventor	DUMAS MILNE EDWARDS, et al.
				Art Unit	Unknown
				Examiner Name	Unassigned
Sheet	3	of	5	Attorney Docket Number	56.US4.CIP

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	X	EP 0786519 A2	07/30/1997	Human Genome Sci.		
	Y	EP 0 625572 A1	11/23/1994	Kanagawa Acad. of Sci.		
	Z	WO 98/31818 A2	07/23/1998	Human Genome Sci.		
	AA	WO 98/45437 A3	10/15/1998	Genetics Institute		
	AB	WO 97/04097 A2	02/06/1997	Genetics Institute		
	AC	WO 99/06549 A2	02/11/1999	Genset		
	AD	WO 98/41624 A1	09/24/1998	Yeda Research & Dev.		

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/978.360
		Filing Date	October 15, 2001
		First Named Inventor	DUMAS MILNE EDWARDS. et al.
		Group Art Unit	Unknown
		Examiner Name	Unassigned
Attorney Docket Number	56.US4.CIP		
Sheet	4	of	5

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AE	ABRAHAM, E.; "Tissue factor inhibition and clinical trail results of tissue factor pathway inhibitor in sepsis"; Crit Care Med 2000, Vol. 28; No. 9 (Suppl.); pg.s S31-S33	
	AF	WOLFSBERG, et al.; "ADAM, a Novel Family of Membrane Proteins Containing A Disintegrin And Metalloprotease Domain: Multipotential Functions in Cell-Cell and Cell-Matrix Interactions"; The Rockefeller University Press; 0021-9525/95/10/275/4; The Journal of Cell Biology; Vol. 131, No. 2; October 1995; pgs. 275-278	
	AG	JACOBS, et al.; "A genetic selection for isolating cDNAs encoding secreted proteins"; Gene, 198 (1997) 289-296; 1997 Elsevier Science B.V.; 0378-1119/97; XP002045919	
	AH	SHIROZU, et al.; "Characterization of Novel Secreted and Membrane Proteins Isolated by the Signal Sequence Trap Method"; Genomics; 37, 273-280 (1996); Article No. 0560; Academic Press, Inc.; 0888-7543/96; XP002054773	
	AI	JACOBS, K., et al.; "A novel method for isolating Eukaryotic cDNA clones encoding secreted proteins"; Journal of Cellular Biochemistry - Supplement; Vol. 21A, 10 March 1995; pg. 19; XP002027246	
	AJ	HILLIER, et al.; "Generation and Analysis of 280,000 Human Expressed Sequence Tags"; Genome Research; 6:807-828; 1996 Cold Spring Harbor Laboratory Press; 1054-9803/96	
	AK	NOMURA, et al.; "Prediction of the Coding Sequences of Unidentified Human Genes. I. The Coding Sequences of 40 New Genes (KIAA0001-KIAA0040) Deduced by Analysis of Randomly Sampled cDNA Clones from Human Immature Myeloid Cell Line KG-1"; DNA Research, Vol. 1, 27-35 (1994)	
	AL	ACCESSION No. Y08617; HALL, L., et al.; "Macaque MDC family of proteins: sequence analysis, tissue distribution and processing in the male reproductive tract"; XP002069695	
	AM	Blast analysis of the polypeptide of SEQ ID NO:177 (Kunitz type protein inhibitors)	
	AN	ALTSCHUL, et al.; "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs"; Nucleic Acids Res. 25:3389-3402 [May 7, 1999]; Query=47-14-1-C3-CL0_5C	
	AM	ALTSCHUL, et al.; "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs"; Nucleic Acids Res. 25:3389-3402 [May 7, 1999];p Query= 78-8-3-E6-CL0_1C	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.